Professional paper
Adalimumab – safe and effective therapy for adolescent patient with severe psoriasis and immune thrombocytopenia.
Mariusz Sikora
orcid.org/0000-0002-6162-9916
; Medical University of WarsawDepartment of Dermatology
Patrycja Gajda
Magdalena Chrabqszcz
Albert Stec
Malgorzata Olszewska
Lidia Rudnicka
Abstract
Psoriasis has been linked to several comorbidities, including metabolic syndrome, atopy, and celiac disease. However, the association between immune thrombocytopenia and psoriasis has rarely been described. We report the case of an adolescent with severe psoriasis and concomitant immune thrombocytopenia who obtained remission during treatment with adalimumab. Increased concentration of tumor necrosis factor-α seems to be a pathogenic linkage and therapeutic target for both diseases.
Keywords
Hrčak ID:
223237
URI
Publication date:
23.7.2019.
Visits: 848 *